-
1
-
-
79957604683
-
Thirty years of hiv and aids: Future challenges and opportunities. Ann. Intern. Med. 154:766-771. 2. Excler jl, rida w, priddy fh, gilmour j, mcdermott ab, kamali a, anzala o, mutua g, sanders ej, koff w, berkley s, fast pe. 2011. Aids vaccines and pre-exposure prophylaxis: Is synergy possible?
-
Dieffenbach CW, Fauci AS. 2011. Thirty years of HIV and AIDS: future challenges and opportunities. Ann. Intern. Med. 154:766-771. 2. Excler JL, Rida W, Priddy FH, Gilmour J, McDermott AB, Kamali A, Anzala O, Mutua G, Sanders EJ, Koff W, Berkley S, Fast PE. 2011. AIDS vaccines and pre-exposure prophylaxis: is synergy possible? AIDS Res. Hum. Retroviruses 27:669-680.
-
(2011)
AIDS Res. Hum. Retroviruses
, vol.27
, pp. 669-680
-
-
Dieffenbach, C.W.1
Fauci, A.S.2
-
2
-
-
78649358100
-
Lessons drawn from recent hiv vaccine efficacy trials. J. Acquir. Immune defic. Syndr. 55(suppl 2):s128-s131. 4. Girard mp, osmanov s, assossou om, kieny mp. 2011. Human immunodeficiency virus (hiv) immunopathogenesis and vaccine development: A review
-
Fuchs JD, Sobieszczyk ME, Hammer SM, Buchbinder SP. 2010. Lessons drawn from recent HIV vaccine efficacy trials. J. Acquir. Immune Defic. Syndr. 55(Suppl 2):S128-S131. 4. Girard MP, Osmanov S, Assossou OM, Kieny MP. 2011. Human immunodeficiency virus (HIV) immunopathogenesis and vaccine development: a review. Vaccine 29:6191-6218.
-
(2010)
Vaccine
, vol.29
, pp. 6191-6218
-
-
Fuchs, J.D.1
Sobieszczyk, M.E.2
Hammer, S.M.3
Buchbinder, S.P.4
-
4
-
-
77958490167
-
Induction of immunity to human immunodeficiency virus type-1 by vaccination
-
McElrath MJ, Haynes BF. 2010. Induction of immunity to human immunodeficiency virus type-1 by vaccination. Immunity 33:542-554.
-
(2010)
Immunity
, vol.33
, pp. 542-554
-
-
McElrath, M.J.1
Haynes, B.F.2
-
5
-
-
73349094086
-
Vaccination with alvac and aidsvax to prevent hiv-1 infection in thailand
-
Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, Premsri N, Namwat C, de Souza M, Adams E, Benenson M, Gurunathan S, Tartaglia J, McNeil JG, Francis DP, Stablein D, Birx DL, Chunsuttiwat S, Khamboonruang C, Thongcharoen P, Robb ML, Michael NL, Kunasol P, Kim JH. 2009. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N. Engl. J. Med. 361: 2209-2220.
-
(2009)
N. Engl. J. Med
, vol.361
, pp. 2209-2220
-
-
Rerks-Ngarm, S.1
Pitisuttithum, P.2
Nitayaphan, S.3
Kaewkungwal, J.4
Chiu, J.5
Paris, R.6
Premsri, N.7
Namwat, C.8
De Souza, M.9
Adams, E.10
Benenson, M.11
Gurunathan, S.12
Tartaglia, J.13
McNeil, J.G.14
Francis, D.P.15
Stablein, D.16
Birx, D.L.17
Chunsuttiwat, S.18
Khamboonruang, C.19
Thongcharoen, P.20
Robb, M.L.21
Michael, N.L.22
Kunasol, P.23
Kim, J.H.24
more..
-
6
-
-
77955518218
-
Attenuated poxvirus vectors mva and nyvac as promising vaccine candidates against hiv/aids. Hum. Vaccines 5:867-871. 9. Pantaleo g, esteban m, jacobs b, tartaglia j. 2010. Poxvirus vectorbased hiv vaccines
-
Esteban M. 2009. Attenuated poxvirus vectors MVA and NYVAC as promising vaccine candidates against HIV/AIDS. Hum. Vaccines 5:867-871. 9. Pantaleo G, Esteban M, Jacobs B, Tartaglia J. 2010. Poxvirus vectorbased HIV vaccines. Curr. Opin. HIV AIDS 5:391-396.
-
(2009)
Curr. Opin. HIV AIDS
, vol.5
, pp. 391-396
-
-
Esteban, M.1
-
7
-
-
36549051636
-
Clinical and immunologic responses to multiple doses of imvamune (modified vaccinia ankara) followed by dryvax challenge
-
Frey SE, Newman FK, Kennedy JS, Sobek V, Ennis FA, Hill H, Yan LK, Chaplin P, Vollmar J, Chaitman BR, Belshe RB. 2007. Clinical and immunologic responses to multiple doses of IMVAMUNE (modified vaccinia Ankara) followed by Dryvax challenge. Vaccine 25:8562-8573.
-
(2007)
Vaccine
, vol.25
, pp. 8562-8573
-
-
Frey, S.E.1
Newman, F.K.2
Kennedy, J.S.3
Sobek, V.4
Ennis, F.A.5
Hill, H.6
Yan, L.K.7
Chaplin, P.8
Vollmar, J.9
Chaitman, B.R.10
Belshe, R.B.11
-
8
-
-
84858294842
-
Biosafety aspects of modified vaccinia virus ankara (mva)-based vectors used for gene therapy or vaccination
-
Verheust C, Goossens M, Pauwels K, Breyer D. 2012. Biosafety aspects of modified vaccinia virus Ankara (MVA)-based vectors used for gene therapy or vaccination. Vaccine 30:2623-2632.
-
(2012)
Vaccine
, vol.30
, pp. 2623-2632
-
-
Verheust, C.1
Goossens, M.2
Pauwels, K.3
Breyer, D.4
-
9
-
-
78649733251
-
Phase i safety and immunogenicity evaluation of mva-cmdr, a multigenic, recombinant modified vaccinia ankara-hiv-1 vaccine candidate
-
doi:10.1371/journal.pone.0013983
-
Currier JR, Ngauy V, de Souza MS, Ratto-Kim S, Cox JH, Polonis VR, Earl P, Moss B, Peel S, Slike B, Sriplienchan S, Thongcharoen P, Paris RM, Robb ML, Kim J, Michael NL, Marovich MA. 2010. Phase I safety and immunogenicity evaluation of MVA-CMDR, a multigenic, recombinant modified vaccinia Ankara-HIV-1 vaccine candidate. PLoS One 5:e13983. doi:10.1371/journal.pone.0013983.
-
(2010)
PLoS One
, vol.5
-
-
Currier, J.R.1
Ngauy, V.2
De Souza, M.S.3
Ratto-Kim, S.4
Cox, J.H.5
Polonis, V.R.6
Earl, P.7
Moss, B.8
Peel, S.9
Slike, B.10
Sriplienchan, S.11
Thongcharoen, P.12
Paris, R.M.13
Robb, M.L.14
Kim, J.15
Michael, N.L.16
Marovich, M.A.17
-
10
-
-
80054003999
-
Safety and immunogenicity of a modified pox vector-based hivaids vaccine candidate expressing env gag pol and nef proteins of hiv-1 subtype b (mva-b) in healthy hiv-1-uninfected volunteers: A phase i clinical trial (risvac02)
-
Garcia F, Bernaldo de Quiros JC, Gomez CE, Perdiguero B, Najera JL, Jimenez V, Garcia-Arriaza J, Guardo AC, Perez I, Diaz-Brito V, Conde MS, Gonzalez N, Alvarez A, Alcami J, Jimenez JL, Pich J, Arnaiz JA, Maleno MJ, Leon A, Munoz-Fernandez MA, Liljestrom P, Weber J, Pantaleo G, Gatell JM, Plana M, Esteban M. 2011. Safety and immunogenicity of a modified pox vector-based HIV/AIDS vaccine candidate expressing Env, Gag, Pol and Nef proteins of HIV-1 subtype B (MVA-B) in healthy HIV-1-uninfected volunteers: a phase I clinical trial (RISVAC02). Vaccine 29:8309-8316.
-
(2011)
Vaccine
, vol.29
, pp. 8309-8316
-
-
Garcia, F.1
Bernaldo De Quiros, J.C.2
Gomez, C.E.3
Perdiguero, B.4
Najera, J.L.5
Jimenez, V.6
Garcia-Arriaza, J.7
Guardo, A.C.8
Perez, I.9
Diaz-Brito, V.10
Conde, M.S.11
Gonzalez, N.12
Alvarez, A.13
Alcami, J.14
Jimenez, J.L.15
Pich, J.16
Arnaiz, J.A.17
Maleno, M.J.18
Leon, A.19
Munoz-Fernandez, M.A.20
Liljestrom, P.21
Weber, J.22
Pantaleo, G.23
Gatell, J.M.24
Plana, M.25
Esteban, M.26
more..
-
11
-
-
33646454992
-
Induction of multifunctional human immunodeficiency virus type 1 (hiv-1)-specific t cells capable of proliferation in healthy subjects by using a prime-boost regimen of dna-and modified vaccinia virus ankara-vectored vaccines expressing hiv-1 gag coupled to cd8-t-cell epitopes
-
Goonetilleke N, Moore S, Dally L, Winstone N, Cebere I, Mahmoud A, Pinheiro S, Gillespie G, Brown D, Loach V, Roberts J, Guimaraes-Walker A, Hayes P, Loughran K, Smith C, De Bont J, Verlinde C, Vooijs D, Schmidt C, Boaz M, Gilmour J, Fast P, Dorrell L, Hanke T, McMichael AJ. 2006. Induction of multifunctional human immunodeficiency virus type 1 (HIV-1)-specific T cells capable of proliferation in healthy subjects by using a prime-boost regimen of DNA-and modified vaccinia virus Ankara-vectored vaccines expressing HIV-1 Gag coupled to CD8-T-cell epitopes. J. Virol. 80:4717-4728.
-
(2006)
J. Virol
, vol.80
, pp. 4717-4728
-
-
Goonetilleke, N.1
Moore, S.2
Dally, L.3
Winstone, N.4
Cebere, I.5
Mahmoud, A.6
Pinheiro, S.7
Gillespie, G.8
Brown, D.9
Loach, V.10
Roberts, J.11
Guimaraes-Walker, A.12
Hayes, P.13
Loughran, K.14
Smith, C.15
De Bont, J.16
Verlinde, C.17
Vooijs, D.18
Schmidt, C.19
Boaz, M.20
Gilmour, J.21
Fast, P.22
Dorrell, L.23
Hanke, T.24
McMichael, A.J.25
more..
-
12
-
-
33846920328
-
Studies of a prophylactic hiv-1 vaccine candidate based on modified vaccinia virus ankara (mva) with and without dna priming: Effects of dosage and route on safety and immunogenicity
-
Peters BS, Jaoko W, Vardas E, Panayotakopoulos G, Fast P, Schmidt C, Gilmour J, Bogoshi M, Omosa-Manyonyi G, Dally L, Klavinskis L, Farah B, Tarragona T, Bart PA, Robinson A, Pieterse C, Stevens W, Thomas R, Barin B, McMichael AJ, McIntyre JA, Pantaleo G, Hanke T, Bwayo J. 2007. Studies of a prophylactic HIV-1 vaccine candidate based on modified vaccinia virus Ankara (MVA) with and without DNA priming: effects of dosage and route on safety and immunogenicity. Vaccine 25:2120-2127.
-
(2007)
Vaccine
, vol.25
, pp. 2120-2127
-
-
Peters, B.S.1
Jaoko, W.2
Vardas, E.3
Panayotakopoulos, G.4
Fast, P.5
Schmidt, C.6
Gilmour, J.7
Bogoshi, M.8
Omosa-Manyonyi, G.9
Dally, L.10
Klavinskis, L.11
Farah, B.12
Tarragona, T.13
Bart, P.A.14
Robinson, A.15
Pieterse, C.16
Stevens, W.17
Thomas, R.18
Barin, B.19
McMichael, A.J.20
McIntyre, J.A.21
Pantaleo, G.22
Hanke, T.23
Bwayo, J.24
more..
-
13
-
-
71949091412
-
A phase 1 study to evaluate the safety and immunogenicity of a recombinant hiv type 1 subtype c-modified vaccinia ankara virus vaccine candidate in indian volunteers
-
Ramanathan VD, Kumar M, Mahalingam J, Sathyamoorthy P, Narayanan PR, Solomon S, Panicali D, Chakrabarty S, Cox J, Sayeed E, Ackland J, Verlinde C, Vooijs D, Loughran K, Barin B, Lombardo A, Gilmour J, Stevens G, Smith MS, Tarragona-Fiol T, Hayes P, Kochhar S, Excler JL, Fast P. 2009. A phase 1 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 subtype C-modified vaccinia Ankara virus vaccine candidate in Indian volunteers. AIDS Res. Hum. Retroviruses 25:1107-1116.
-
(2009)
AIDS Res. Hum. Retroviruses
, vol.25
, pp. 1107-1116
-
-
Ramanathan, V.D.1
Kumar, M.2
Mahalingam, J.3
Sathyamoorthy, P.4
Narayanan, P.R.5
Solomon, S.6
Panicali, D.7
Chakrabarty, S.8
Cox, J.9
Sayeed, E.10
Ackland, J.11
Verlinde, C.12
Vooijs, D.13
Loughran, K.14
Barin, B.15
Lombardo, A.16
Gilmour, J.17
Stevens, G.18
Smith, M.S.19
Tarragona-Fiol, T.20
Hayes, P.21
Kochhar, S.22
Excler, J.L.23
Fast, P.24
more..
-
14
-
-
67649338409
-
Recombinant modified vaccinia ankara (mva) effectively boosts dna-primed hiv-specific immune responses in humans despite pre-existing vaccinia immunity
-
Gudmundsdotter L, Nilsson C, Brave A, Hejdeman B, Earl P, Moss B, Robb M, Cox J, Michael N, Marovich M, Biberfeld G, Sandstrom E, Wahren B. 2009. Recombinant modified vaccinia Ankara (MVA) effectively boosts DNA-primed HIV-specific immune responses in humans despite pre-existing vaccinia immunity. Vaccine 27:4468-4474.
-
(2009)
Vaccine
, vol.27
, pp. 4468-4474
-
-
Gudmundsdotter, L.1
Nilsson, C.2
Brave, A.3
Hejdeman, B.4
Earl, P.5
Moss, B.6
Robb, M.7
Cox, J.8
Michael, N.9
Marovich, M.10
Biberfeld, G.11
Sandstrom, E.12
Wahren, B.13
-
15
-
-
80053948074
-
Broad and potent immune responses to a low dose intradermal hiv-1 dna boosted with hiv-1 recombinant mva among healthy adults in tanzania
-
Bakari M, Aboud S, Nilsson C, Francis J, Buma D, Moshiro C, Aris EA, Lyamuya EF, Janabi M, Godoy-Ramirez K, Joachim A, Polonis VR, Brave A, Earl P, Robb M, Marovich M, Wahren B, Pallangyo K, Biberfeld G, Mhalu F, Sandstrom E. 2011. Broad and potent immune responses to a low dose intradermal HIV-1 DNA boosted with HIV-1 recombinant MVA among healthy adults in Tanzania. Vaccine 29:8417-8428.
-
(2011)
Vaccine
, vol.29
, pp. 8417-8428
-
-
Bakari, M.1
Aboud, S.2
Nilsson, C.3
Francis, J.4
Buma, D.5
Moshiro, C.6
Aris, E.A.7
Lyamuya, E.F.8
Janabi, M.9
Godoy-Ramirez, K.10
Joachim, A.11
Polonis, V.R.12
Brave, A.13
Earl, P.14
Robb, M.15
Marovich, M.16
Wahren, B.17
Pallangyo, K.18
Biberfeld, G.19
Mhalu, F.20
Sandstrom, E.21
more..
-
16
-
-
80053078021
-
Hiv-dna priming alters t cell responses to hiv-adenovirus vaccine even when responses to dna are undetectable
-
De Rosa SC, Thomas EP, Bui J, Huang Y, deCamp A, Morgan C, Kalams SA, Tomaras GD, Akondy R, Ahmed R, Lau CY, Graham BS, Nabel GJ, McElrath MJ. 2011. HIV-DNA priming alters T cell responses to HIV-adenovirus vaccine even when responses to DNA are undetectable. J. Immunol. 187:3391-3401.
-
(2011)
J. Immunol.
, vol.187
, pp. 3391-3401
-
-
De Rosa, S.C.1
Thomas, E.P.2
Bui, J.3
Huang, Y.4
DeCamp, A.5
Morgan, C.6
Kalams, S.A.7
Tomaras, G.D.8
Akondy, R.9
Ahmed, R.10
Lau, C.Y.11
Graham, B.S.12
Nabel, G.J.13
McElrath, M.J.14
-
17
-
-
79751487021
-
Phase 1 safety and immunogenicity testing of DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles
-
Goepfert PA, Elizaga ML, Sato A, Qin L, Cardinali M, Hay CM, Hural J, DeRosa SC, DeFawe OD, Tomaras GD, Montefiori DC, Xu Y, Lai L, Kalams SA, Baden LR, Frey SE, Blattner WA, Wyatt LS, Moss B, Robinson HL. 2011. Phase 1 safety and immunogenicity testing of DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles. J. Infect. Dis. 203:610-619.
-
(2011)
J. Infect. Dis.
, vol.203
, pp. 610-619
-
-
Goepfert, P.A.1
Elizaga, M.L.2
Sato, A.3
Qin, L.4
Cardinali, M.5
Hay, C.M.6
Hural, J.7
DeRosa, S.C.8
DeFawe, O.D.9
Tomaras, G.D.10
Montefiori, D.C.11
Xu, Y.12
Lai, L.13
Kalams, S.A.14
Baden, L.R.15
Frey, S.E.16
Blattner, W.A.17
Wyatt, L.S.18
Moss, B.19
Robinson, H.L.20
more..
-
18
-
-
84860337949
-
Dna and modified vaccinia ankara (mva) human immunodeficiency virus type 1 (hiv-1) vaccines encoding multiple cytotoxic and helper t-lymphocyte epitopes are safe but weakly immunogenic in hiv-1-uninfected, vaccinia-naive adults
-
Gorse GJ, Newman MJ, Decamp A, Hay CM, De Rosa SC, Noonan E, Livingston BD, Fuchs JD, Kalams SA, Cassis-Ghavami FL. 2012. DNA and modified vaccinia Ankara (MVA) human immunodeficiency virus type 1 (HIV-1) vaccines encoding multiple cytotoxic and helper T-lymphocyte epitopes are safe but weakly immunogenic in HIV-1-uninfected, vaccinia-naive adults. Clin. Vaccine Immunol. 19:649-658.
-
(2012)
Clin. Vaccine Immunol
, vol.19
, pp. 649-658
-
-
Gorse, G.J.1
Newman, M.J.2
Decamp, A.3
Hay, C.M.4
De Rosa, S.C.5
Noonan, E.6
Livingston, B.D.7
Fuchs, J.D.8
Kalams, S.A.9
Cassis-Ghavami, F.L.10
-
19
-
-
79951721121
-
A phase i trial of preventive hiv vaccination with heterologous poxviral-vectors containing matching hiv-1 inserts in healthy hiv-uninfected subjects
-
Keefer MC, Frey SE, Elizaga M, Metch B, De Rosa SC, Barroso PF, Tomaras G, Cardinali M, Goepfert P, Kalichman A, Philippon V, McElrath MJ, Jin X, Ferrari G, Defawe OD, Mazzara GP, Montefiori D, Pensiero M, Panicali DL, Corey L. 2011. A phase I trial of preventive HIV vaccination with heterologous poxviral-vectors containing matching HIV-1 inserts in healthy HIV-uninfected subjects. Vaccine 29:1948-1958.
-
(2011)
Vaccine
, vol.29
, pp. 1948-1958
-
-
Keefer, M.C.1
Frey, S.E.2
Elizaga, M.3
Metch, B.4
De Rosa, S.C.5
Barroso, P.F.6
Tomaras, G.7
Cardinali, M.8
Goepfert, P.9
Kalichman, A.10
Philippon, V.11
McElrath, M.J.12
Jin, X.13
Ferrari, G.14
Defawe, O.D.15
Mazzara, G.P.16
Montefiori, D.17
Pensiero, M.18
Panicali, D.L.19
Corey, L.20
more..
-
20
-
-
77749322238
-
Priming immunization with dna augments immunogenicity of recombinant adenoviral vectors for both hiv-1 specific antibody and t-cell responses
-
doi:10.1371/journal .pone.0009015
-
Koup RA, Roederer M, Lamoreaux L, Fischer J, Novik L, Nason MC, Larkin BD, Enama ME, Ledgerwood JE, Bailer RT, Mascola JR, Nabel GJ, Graham BS. 2010. Priming immunization with DNA augments immunogenicity of recombinant adenoviral vectors for both HIV-1 specific antibody and T-cell responses. PLoS One 5:e9015. doi:10.1371/journal .pone.0009015.
-
(2010)
PLoS One
, vol.5
-
-
Koup, R.A.1
Roederer, M.2
Lamoreaux, L.3
Fischer, J.4
Novik, L.5
Nason, M.C.6
Larkin, B.D.7
Enama, M.E.8
Ledgerwood, J.E.9
Bailer, R.T.10
Mascola, J.R.11
Nabel, G.J.12
Graham, B.S.13
-
21
-
-
44749088148
-
Ev02: A phase i trial to compare the safety and immunogenicity of hiv dna-c prime-nyvac-c boost to nyvac-c alone
-
McCormack S, Stöhr W, Barber T, Bart Harari P-AA, Moog C, Ciuffreda D, Cellerai C, Cowen M, Gamboni R, Burnet S, Legg K, Brodnicki E, Wolf H, Wagner R, Heeney J, Frachette Tartaglia M-JJ, Babiker A, Pantaleo G, Weber J. 2008. EV02: a phase I trial to compare the safety and immunogenicity of HIV DNA-C prime-NYVAC-C boost to NYVAC-C alone. Vaccine 26:3162-3174.
-
(2008)
Vaccine
, vol.26
, pp. 3162-3174
-
-
McCormack, S.1
Stöhr, W.2
Barber, T.3
Bart Harari, P.-A.A.4
Moog, C.5
Ciuffreda, D.6
Cellerai, C.7
Cowen, M.8
Gamboni, R.9
Burnet, S.10
Legg, K.11
Brodnicki, E.12
Wolf, H.13
Wagner, R.14
Heeney, J.15
Frachette Tartaglia, M.-J.J.16
Babiker, A.17
Pantaleo, G.18
Weber, J.19
-
22
-
-
80053983802
-
Dna/nyvac vaccine regimen induces hiv-specific cd4 and cd8 t-cell responses in intestinal mucosa
-
Perreau M, Welles HC, Harari A, Hall O, Martin R, Maillard M, Dorta G, Bart PA, Kremer EJ, Tartaglia J, Wagner R, Esteban M, Levy Y, Pantaleo G. 2011. DNA/NYVAC vaccine regimen induces HIV-specific CD4 and CD8 T-cell responses in intestinal mucosa. J. Virol. 85:9854-9862.
-
(2011)
J. Virol
, Issue.85
, pp. 9854-9862
-
-
Perreau, M.1
Welles, H.C.2
Harari, A.3
Hall, O.4
Martin, R.5
Maillard, M.6
Dorta, G.7
Bart, P.A.8
Kremer, E.J.9
Tartaglia, J.10
Wagner, R.11
Esteban, M.12
Levy, Y.13
Pantaleo, G.14
-
23
-
-
54949106244
-
Broad immunogenicity of a multigene, multiclade hiv-1 dna vaccine boosted with heterologous hiv-1 recombinant modified vaccinia virus ankara
-
Sandstrom E, Nilsson C, Hejdeman B, Brave A, Bratt G, Robb M, Cox J, Vancott T, Marovich M, Stout R, Aboud S, Bakari M, Pallangyo K, Ljungberg K, Moss B, Earl P, Michael N, Birx D, Mhalu F, Wahren B, Biberfeld G. 2008. Broad immunogenicity of a multigene, multiclade HIV-1 DNA vaccine boosted with heterologous HIV-1 recombinant modified vaccinia virus Ankara. J. Infect. Dis. 198:1482-1490.
-
(2008)
J. Infect. Dis
, vol.198
, pp. 1482-1490
-
-
Sandstrom, E.1
Nilsson, C.2
Hejdeman, B.3
Brave, A.4
Bratt, G.5
Robb, M.6
Cox, J.7
Vancott, T.8
Marovich, M.9
Stout, R.10
Aboud, S.11
Bakari, M.12
Pallangyo, K.13
Ljungberg, K.14
Moss, B.15
Earl, P.16
Michael, N.17
Birx, D.18
Mhalu, F.19
Wahren, B.20
Biberfeld, G.21
more..
-
24
-
-
0036113771
-
Critical rolefor env as well as gag-pol in control of a simian-human immunodeficiency virus 89.6p challenge by a dna prime/recombinant modified vaccinia virus ankara vaccine
-
Amara RR, Smith JM, Staprans SI, Montefiori DC, Villinger F, Altman JD, O'Neil SP, Kozyr NL, Xu Y, Wyatt LS, Earl PL, Herndon JG, McNicholl JM, McClure HM, Moss B, Robinson HL. 2002. Critical rolefor Env as well as Gag-Pol in control of a simian-human immunodeficiency virus 89.6P challenge by a DNA prime/recombinant modified vaccinia virus Ankara vaccine. J. Virol. 76:6138-6146.
-
(2002)
J. Virol
, vol.76
, pp. 6138-6146
-
-
Amara, R.R.1
Smith, J.M.2
Staprans, S.I.3
Montefiori, D.C.4
Villinger, F.5
Altman, J.D.6
O'Neil, S.P.7
Kozyr, N.L.8
Xu, Y.9
Wyatt, L.S.10
Earl, P.L.11
Herndon, J.G.12
McNicholl, J.M.13
McClure, H.M.14
Moss, B.15
Robinson, H.L.16
-
25
-
-
0035025623
-
Reduction of simian-human immunodeficiency virus 89.6p viremia in rhesus monkeys by recombinant modified vaccinia virus ankara vaccination
-
Barouch DH, Santra S, Kuroda MJ, Schmitz JE, Plishka R, Buckler-White A, Gaitan AE, Zin R, Nam JH, Wyatt LS, Lifton MA, Nickerson CE, Moss B, Montefiori DC, Hirsch VM, Letvin NL. 2001. Reduction of simian-human immunodeficiency virus 89.6P viremia in rhesus monkeys by recombinant modified vaccinia virus Ankara vaccination. J. Virol. 75: 5151-5158.
-
(2001)
J. Virol
, vol.75
, pp. 5151-5158
-
-
Barouch, D.H.1
Santra, S.2
Kuroda, M.J.3
Schmitz, J.E.4
Plishka, R.5
Buckler-White, A.6
Gaitan, A.E.7
Zin, R.8
Nam, J.H.9
Wyatt, L.S.10
Lifton, M.A.11
Nickerson, C.E.12
Moss, B.13
Montefiori, D.C.14
Hirsch, V.M.15
Letvin, N.L.16
-
26
-
-
12144289214
-
Control of simianhuman immunodeficiency virus viremia and disease progression after il-2-augmented dna-modified vaccinia virus ankara nasal vaccination in nonhuman primates
-
Bertley FM, Kozlowski PA, Wang SW, Chappelle J, Patel J, Sonuyi O, Mazzara G, Montefiori D, Carville A, Mansfield KG, Aldovini A. 2004. Control of simian/human immunodeficiency virus viremia and disease progression after IL-2-augmented DNA-modified vaccinia virus Ankara nasal vaccination in nonhuman primates. J. Immunol. 172:3745-3757.
-
(2004)
J. Immunol
, vol.172
, pp. 3745-3757
-
-
Bertley, F.M.1
Kozlowski, P.A.2
Wang, S.W.3
Chappelle, J.4
Patel, J.5
Sonuyi, O.6
Mazzara, G.7
Montefiori, D.8
Carville, A.9
Mansfield, K.G.10
Aldovini, A.11
-
27
-
-
84862818488
-
Inclusion of a crf01-ae hiv envelope protein boost with a dna mva prime-boost vaccine: Impact on humoral and cellular immunogenicity and viral load reduction after shiv-e challenge
-
Cox JH, Ferrari MG, Earl P, Lane JR, Jagodzinski LL, Polonis VR, Kuta EG, Boyer JD, Ratto-Kim S, Eller LA, Pham DT, Hart L, Montefiori D, Ferrari G, Parrish S, Weiner DB, Moss B, Kim JH, Birx D, Vancott TC. 2012. Inclusion of a CRF01-AE HIV envelope protein boost with a DNA/ MVA prime-boost vaccine: impact on humoral and cellular immunogenicity and viral load reduction after SHIV-E challenge. Vaccine 30:1830-1840.
-
(2012)
Vaccine
, vol.30
, pp. 1830-1840
-
-
Cox, J.H.1
Ferrari, M.G.2
Earl, P.3
Lane, J.R.4
Jagodzinski, L.L.5
Polonis, V.R.6
Kuta, E.G.7
Boyer, J.D.8
Ratto-Kim, S.9
Eller, L.A.10
Pham, D.T.11
Hart, L.12
Montefiori, D.13
Ferrari, G.14
Parrish, S.15
Weiner, D.B.16
Moss, B.17
Kim, J.H.18
Birx, D.19
Vancott, T.C.20
more..
-
28
-
-
79953170206
-
Long-term control of simian immunodeficiency virus mac251 viremia to undetectable levels in half of infected female rhesus macaques nasally vaccinated with simian immunodeficiency virus dna/recombinant modified vaccinia virus ankara
-
Manrique M, Kozlowski PA, Cobo-Molinos A, Wang SW, Wilson RL, Montefiori DC, Mansfield KG, Carville A, Aldovini A. 2011. Long-term control of simian immunodeficiency virus mac251 viremia to undetectable levels in half of infected female rhesus macaques nasally vaccinated with simian immunodeficiency virus DNA/recombinant modified vaccinia virus Ankara. J. Immunol. 186:3581-3593.
-
(2011)
J. Immunol
, vol.186
, pp. 3581-3593
-
-
Manrique, M.1
Kozlowski, P.A.2
Cobo-Molinos, A.3
Wang, S.W.4
Wilson, R.L.5
Montefiori, D.C.6
Mansfield, K.G.7
Carville, A.8
Aldovini, A.9
-
29
-
-
41449096780
-
Dna-mva vaccine protection after x4 shiv challenge in macaques correlates with day-of-challenge antiviral cd4-cell-mediated immunity levels and postchallenge preservation of cd4-t cell memory
-
Manrique M, Micewicz E, Kozlowski PA, Wang SW, Aurora D, Wilson RL, Ghebremichael M, Mazzara G, Montefiori D, Carville A, Mansfield KG, Aldovini A. 2008. DNA-MVA vaccine protection after X4 SHIV challenge in macaques correlates with day-of-challenge antiviral CD4-cell-mediated immunity levels and postchallenge preservation of CD4-T cell memory. AIDS Res. Hum. Retroviruses 24:505-519.
-
(2008)
AIDS Res. Hum. Retroviruses
, vol.24
, pp. 505-519
-
-
Manrique, M.1
Micewicz, E.2
Kozlowski, P.A.3
Wang, S.W.4
Aurora, D.5
Wilson, R.L.6
Ghebremichael, M.7
Mazzara, G.8
Montefiori, D.9
Carville, A.10
Mansfield, K.G.11
Aldovini, A.12
-
30
-
-
80052285787
-
High antibody and cellular responses induced to hiv-1 clade c envelope following dna vaccines delivered by electroporation
-
Yin J, Dai A, Lecureux J, Arango T, Kutzler MA, Yan J, Lewis MG, Khan A, Sardesai NY, Montefiore D, Ruprecht R, Weiner DB, Boyer JD. 2011. High antibody and cellular responses induced to HIV-1 clade C envelope following DNA vaccines delivered by electroporation. Vaccine 29:6763-6770.
-
(2011)
Vaccine
, vol.29
, pp. 6763-6770
-
-
Yin, J.1
Dai, A.2
Lecureux, J.3
Arango, T.4
Kutzler, M.A.5
Yan, J.6
Lewis, M.G.7
Khan, A.8
Sardesai, N.Y.9
Montefiore, D.10
Ruprecht, R.11
Weiner, D.B.12
Boyer, J.D.13
-
31
-
-
84863191097
-
Measurements of immune responses for establishing correlates of vaccine protection against hiv
-
Burgers WA, Manrique A, Masopust D, McKinnon LR, Reynolds MR, Rolland M, Blish C, Chege GK, Curran R, Fischer W, Herrera C, Sather DN. 2012. Measurements of immune responses for establishing correlates of vaccine protection against HIV. AIDS Res. Hum. Retroviruses. 28:641-648.
-
(2012)
AIDS Res. Hum. Retroviruses
, vol.28
, pp. 641-648
-
-
Burgers, W.A.1
Manrique, A.2
Masopust, D.3
McKinnon, L.R.4
Reynolds, M.R.5
Rolland, M.6
Blish, C.7
Chege, G.K.8
Curran, R.9
Fischer, W.10
Herrera, C.11
Sather, D.N.12
-
32
-
-
78650531619
-
Living in a house of cards: Re-evaluating cd8-t-cell immune correlates against hiv
-
Makedonas G, Betts MR. 2011. Living in a house of cards: re-evaluating CD8-T-cell immune correlates against HIV. Immunol. Rev. 239:109-124.
-
(2011)
Immunol. Rev
, vol.239
, pp. 109-124
-
-
Makedonas, G.1
Betts, M.R.2
-
33
-
-
40549120282
-
Design, construction, and characterization of a dual-promoter multigenic dna vaccine directed against an hiv-1 subtype c/b' recombinant
-
Huang Y, Chen Z, Zhang W, Gurner D, Song Y, Gardiner DF, Ho DD. 2008. Design, construction, and characterization of a dual-promoter multigenic DNA vaccine directed against an HIV-1 subtype C/B' recombinant. J. Acquir. Immune Defic. Syndr. 47:403-411. 37. Vasan S, Schlesinger SJ, Huang Y, Hurley A, Lombardo A, Chen Z, Than S, Adesanya P, Bunce C, Boaz M, Boyle R, Sayeed E, Clark L, Dugin D, Schmidt C, Song Y, Seamons L, Dally L, Ho M, Smith C, Markowitz M, Cox J, Gill DK, Gilmour J, Keefer MC, Fast P, Ho DD. 2010. Phase 1 safety and immunogenicity evaluation of ADVAX, a multigenic, DNA-based clade C/B' HIV-1 candidate vaccine. PLoS One 5:e8617. doi:10.1371/journal.pone. 0008617.
-
(2008)
J. Acquir. Immune Defic. Syndr
, vol.47
, pp. 403-411
-
-
Huang, Y.1
Chen, Z.2
Zhang, W.3
Gurner, D.4
Song, Y.5
Gardiner, D.F.6
Ho, D.D.7
-
34
-
-
33750702683
-
-
ISBN 978-1-904610-00-7. BARQA, Ipswich, United Kingdom. 39. Vasan S, Hurley A, Schlesinger SJ, Hannaman D, Gardiner DF, Dugin DP, Boente-Carrera M, Vittorino R, Caskey M, Andersen J, Huang Y, Cox JH, Tarragona-Fiol T, Gill DK, Cheeseman H, Clark L, Dally L, Smith C, Schmidt C, Park HH, Kopycinski JT, Gilmour J, Fast P, Bernard R, Ho DD. 2011. Electroporation enhances the immunogenicity of an HIV-1 DNA vaccine candidate in healthy volunteers. PLoS One 6:e19252. doi:10.1371/journal.pone.0019252
-
Stiles T, Grant V. 2011. Good clinical laboratory practice (GCLP). A quality system for laboratories that undertake the analysis of samples from clinical trials, p 1-18. ISBN 978-1-904610-00-7. BARQA, Ipswich, United Kingdom. 39. Vasan S, Hurley A, Schlesinger SJ, Hannaman D, Gardiner DF, Dugin DP, Boente-Carrera M, Vittorino R, Caskey M, Andersen J, Huang Y, Cox JH, Tarragona-Fiol T, Gill DK, Cheeseman H, Clark L, Dally L, Smith C, Schmidt C, Park HH, Kopycinski JT, Gilmour J, Fast P, Bernard R, Ho DD. 2011. Electroporation enhances the immunogenicity of an HIV-1 DNA vaccine candidate in healthy volunteers. PLoS One 6:e19252. doi:10.1371/journal.pone.0019252.
-
(2011)
Good Clinical Laboratory Practice (GCLP). A quality system for laboratories that undertake the Analysis of Samples from Clinical Trials
, pp. 1-18
-
-
Stiles, T.1
Grant, V.2
-
35
-
-
59649110914
-
Concordant proficiency in measurement of t-cell immunity in human immunodeficiency virus vaccine clinical trials by peripheral blood mononuclear cell and enzyme-linked immunospot assays in laboratories from three continents
-
Boaz MJ, Hayes P, Tarragona T, Seamons L, Cooper A, Birungi J, Kitandwe P, Semaganda A, Kaleebu P, Stevens G, Anzala O, Farah B, Ogola S, Indangasi J, Mhlanga P, Van Eeden M, Thakar M, Pujari A, Mishra S, Goonetilleke N, Moore S, Mahmoud A, Sathyamoorthy P, Mahalingam J, Narayanan PR, Ramanathan VD, Cox JH, Dally L, Gill DK, Gilmour J. 2009. Concordant proficiency in measurement of T-cell immunity in human immunodeficiency virus vaccine clinical trials by peripheral blood mononuclear cell and enzyme-linked immunospot assays in laboratories from three continents. Clin. Vaccine Immunol. 16: 147-155.
-
(2009)
Clin. Vaccine Immunol
, vol.16
, pp. 147-155
-
-
Boaz, M.J.1
Hayes, P.2
Tarragona, T.3
Seamons, L.4
Cooper, A.5
Birungi, J.6
Kitandwe, P.7
Semaganda, A.8
Kaleebu, P.9
Stevens, G.10
Anzala, O.11
Farah, B.12
Ogola, S.13
Indangasi, J.14
Mhlanga, P.15
Van Eeden, M.16
Thakar, M.17
Pujari, A.18
Mishra, S.19
Goonetilleke, N.20
Moore, S.21
Mahmoud, A.22
Sathyamoorthy, P.23
Mahalingam, J.24
Narayanan, P.R.25
Ramanathan, V.D.26
Cox, J.H.27
Dally, L.28
Gill, D.K.29
Gilmour, J.30
more..
-
36
-
-
78650779470
-
Equivalence of elispot assays demonstrated between major hiv network laboratories
-
doi:10.1371/journal.pone.0014330
-
Gill DK, Huang Y, Levine GL, Sambor A, Carter DK, Sato A, Kopycinski J, Hayes P, Hahn B, Birungi J, Tarragona-Fiol T, Wan H, Randles M, Cooper AR, Ssemaganda A, Clark L, Kaleebu P, Self SG, Koup R, Wood B, McElrath MJ, Cox JH, Hural J, Gilmour J. 2010. Equivalence of ELISpot assays demonstrated between major HIV network laboratories. PLoS One 5:e14330. doi:10.1371/journal.pone. 0014330.
-
(2010)
PLoS One
, vol.5
-
-
Gill, D.K.1
Huang, Y.2
Levine, G.L.3
Sambor, A.4
Carter, D.K.5
Sato, A.6
Kopycinski, J.7
Hayes, P.8
Hahn, B.9
Birungi, J.10
Tarragona-Fiol, T.11
Wan, H.12
Randles, M.13
Cooper, A.R.14
Ssemaganda, A.15
Clark, L.16
Kaleebu, P.17
Self, S.G.18
Koup, R.19
Wood, B.20
McElrath, M.J.21
Cox, J.H.22
Hural, J.23
Gilmour, J.24
more..
-
37
-
-
0036469827
-
A panel ofmhcclass i restricted viral peptides for use as a quality control for vaccine trial elispot assays
-
Currier J, Kuta E, Turk E, Earhart L, Loomis-Price L, Janetzki S, Ferrari G, Birx D, Cox J. 2002. A panel ofMHCclass I restricted viral peptides for use as a quality control for vaccine trial ELISPOT assays. J. Immunol. Methods 260:157-172.
-
(2002)
J. Immunol. Methods
, vol.260
, pp. 157-172
-
-
Currier, J.1
Kuta, E.2
Turk, E.3
Earhart, L.4
Loomis-Price, L.5
Janetzki, S.6
Ferrari, G.7
Birx, D.8
Cox, J.9
-
38
-
-
76449116461
-
Viral inhibition assay: A cd8 t cell neutralization assay for use in clinical trials of hiv-1 vaccine candidates
-
Spentzou A, Bergin P, Gill D, Cheeseman H, Ashraf A, Kaltsidis H, Cashin-Cox M, Anjarwalla I, Steel A, Higgs C, Pozniak A, Piechocka-Trocha A, Wong J, Anzala O, Karita E, Dally L, Gotch F, Walker B, Gilmour J, Hayes P. 2010. Viral inhibition assay: a CD8 T cell neutralization assay for use in clinical trials of HIV-1 vaccine candidates. J. Infect. Dis. 201:720-729.
-
(2010)
J. Infect. Dis
, Issue.201
, pp. 720-729
-
-
Spentzou, A.1
Bergin, P.2
Gill, D.3
Cheeseman, H.4
Ashraf, A.5
Kaltsidis, H.6
Cashin-Cox, M.7
Anjarwalla, I.8
Steel, A.9
Higgs, C.10
Pozniak, A.11
Piechocka-Trocha, A.12
Wong, J.13
Anzala, O.14
Karita, E.15
Dally, L.16
Gotch, F.17
Walker, B.18
Gilmour, J.19
Hayes, P.20
more..
-
40
-
-
33745961311
-
Excellent safety and tolerability of the human immunodeficiency virus type 1 pga2/js2 plasmid dna priming vector vaccine in hiv type 1 uninfected adults
-
Mulligan MJ, Russell ND, Celum C, Kahn J, Noonan E, Montefiori DC, Ferrari G, Weinhold KJ, Smith JM, Amara RR, Robinson HL. 2006. Excellent safety and tolerability of the human immunodeficiency virus type 1 pGA2/JS2 plasmid DNA priming vector vaccine in HIV type 1 uninfected adults. AIDS Res. Hum. Retroviruses 22:678-683
-
(2006)
AIDS Res. Hum. Retroviruses
, vol.22
, pp. 678-683
-
-
Mulligan, M.J.1
Russell, N.D.2
Celum, C.3
Kahn, J.4
Noonan, E.5
Montefiori, D.C.6
Ferrari, G.7
Weinhold, K.J.8
Smith, J.M.9
Amara, R.R.10
Robinson, H.L.11
-
41
-
-
77951695279
-
Dna vaccines: Developing new strategies against cancer
-
doi:10.1155/2010/174378
-
Fioretti D, Iurescia S, Fazio VM, Rinaldi M. 2010. DNA vaccines: developing new strategies against cancer. J. Biomed. Biotechnol. 2010: 174378. doi:10.1155/2010/174378.
-
(2010)
J. Biomed. Biotechnol
, Issue.2010
, pp. 174378
-
-
Fioretti, D.1
Iurescia, S.2
Fazio, V.M.3
Rinaldi, M.4
-
42
-
-
80053366029
-
Selected approaches for increasing hiv dna vaccine immunogenicity in vivo
-
Hutnick NA, Myles DJ, Bian CB, Muthumani K, Weiner DB. 2011. Selected approaches for increasing HIV DNA vaccine immunogenicity in vivo. Curr. Opin. Virol. 1:233-240.
-
(2011)
Curr. Opin. Virol
, Issue.1
, pp. 233-240
-
-
Hutnick, N.A.1
Myles, D.J.2
Bian, C.B.3
Muthumani, K.4
Weiner, D.B.5
-
43
-
-
71949122352
-
Comparative cellmediated immunogenicity of dnadna dnaadenovirus type 5 (ad5) or ad5ad5 hiv-1 clade b gag vaccine prime-boost regimens
-
Asmuth DM, Brown EL, DiNubile MJ, Sun X, del Rio C, Harro C, Keefer MC, Kublin JG, Dubey SA, Kierstead LS, Casimiro DR, Shiver JW, Robertson MN, Quirk EK, Mehrotra DV. 2010. Comparative cellmediated immunogenicity of DNA/DNA, DNA/adenovirus type 5 (Ad5), or Ad5/Ad5 HIV-1 clade B gag vaccine prime-boost regimens. J. Infect. Dis. 201:132-141.
-
(2010)
J. Infect. Dis.
, vol.201
, pp. 132-141
-
-
Asmuth, D.M.1
Brown, E.L.2
DiNubile, M.J.3
Sun, X.4
Del Rio, C.5
Harro, C.6
Keefer, M.C.7
Kublin, J.G.8
Dubey, S.A.9
Kierstead, L.S.10
Casimiro, D.R.11
Shiver, J.W.12
Robertson, M.N.13
Quirk, E.K.14
Mehrotra, D.V.15
-
44
-
-
33845412550
-
Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine
-
Graham BS, Koup RA, Roederer M, Bailer RT, Enama ME, Moodie Z, Martin JE, McCluskey MM, Chakrabarti BK, Lamoreaux L, Andrews CA, Gomez PL, Mascola JR, Nabel GJ. 2006. Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine. J. Infect. Dis. 194:1650-1660.
-
(2006)
J. Infect. Dis.
, vol.194
, pp. 1650-1660
-
-
Graham, B.S.1
Koup, R.A.2
Roederer, M.3
Bailer, R.T.4
Enama, M.E.5
Moodie, Z.6
Martin, J.E.7
McCluskey, M.M.8
Chakrabarti, B.K.9
Lamoreaux, L.10
Andrews, C.A.11
Gomez, P.L.12
Mascola, J.R.13
Nabel, G.J.14
-
45
-
-
77958498605
-
Safety and immunogenicity study of multiclade hiv-1 adenoviral vector vaccine alone or as boost following a multiclade hiv-1 dna vaccine in africa
-
doi:10.1371/journal.pone.0012873
-
Jaoko W, Karita E, Kayitenkore K, Omosa-Manyonyi G, Allen S, Than S, Adams EM, Graham BS, Koup RA, Bailer RT, Smith C, Dally L, Farah B, Anzala O, Muvunyi CM, Bizimana J, Tarragona-Fiol T, Bergin PJ, Hayes P, Ho M, Loughran K, Komaroff W, Stevens G, Thomson H, Boaz MJ, Cox JH, Schmidt C, Gilmour J, Nabel GJ, Fast P, Bwayo J. 2010. Safety and immunogenicity study of multiclade HIV-1 adenoviral vector vaccine alone or as boost following a multiclade HIV-1 DNA vaccine in Africa. PLoS One 5:e12873. doi:10.1371/journal.pone.0012873.
-
(2010)
PLoS One
, vol.5
-
-
Jaoko, W.1
Karita, E.2
Kayitenkore, K.3
Omosa-Manyonyi, G.4
Allen, S.5
Than, S.6
Adams, E.M.7
Graham, B.S.8
Koup, R.A.9
Bailer, R.T.10
Smith, C.11
Dally, L.12
Farah, B.13
Anzala, O.14
Muvunyi, C.M.15
Bizimana, J.16
Tarragona-Fiol, T.17
Bergin, P.J.18
Hayes, P.19
Ho, M.20
Loughran, K.21
Komaroff, W.22
Stevens, G.23
Thomson, H.24
Boaz, M.J.25
Cox, J.H.26
Schmidt, C.27
Gilmour, J.28
Nabel, G.J.29
Fast, P.30
Bwayo, J.31
more..
-
46
-
-
29044440477
-
Comparative evaluation of three different intramuscular delivery methods fordnaimmunization in a nonhuman primate animal model
-
Rao SS, Gomez P, Mascola JR, Dang V, Krivulka GR, Yu F, Lord CI, Shen L, Bailer R, Nabel GJ, Letvin NL. 2006. Comparative evaluation of three different intramuscular delivery methods forDNAimmunization in a nonhuman primate animal model. Vaccine 24:367-373.
-
(2006)
Vaccine
, vol.24
, pp. 367-373
-
-
Rao, S.S.1
Gomez, P.2
Mascola, J.R.3
Dang, V.4
Krivulka, G.R.5
Yu, F.6
Lord, C.I.7
Shen, L.8
Bailer, R.9
Nabel, G.J.10
Letvin, N.L.11
-
47
-
-
38749132973
-
An hiv-1 clade c dna prime, nyvac boost vaccine regimen induces reliable, polyfunctional, and long-lasting t cell responses
-
Harari A, Bart PA, Stohr W, Tapia G, Garcia M, Medjitna-Rais E, Burnet S, Cellerai C, Erlwein O, Barber T, Moog C, Liljestrom P, Wagner R, Wolf H, Kraehenbuhl JP, Esteban M, Heeney J, Frachette MJ, Tartaglia J, McCormack S, Babiker A, Weber J, Pantaleo G. 2008. An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses. J. Exp. Med. 205:63-77.
-
(2008)
J. Exp. Med
, vol.205
, pp. 63-77
-
-
Harari, A.1
Bart, P.A.2
Stohr, W.3
Tapia, G.4
Garcia, M.5
Medjitna-Rais, E.6
Burnet, S.7
Cellerai, C.8
Erlwein, O.9
Barber, T.10
Moog, C.11
Liljestrom, P.12
Wagner, R.13
Wolf, H.14
Kraehenbuhl, J.P.15
Esteban, M.16
Heeney, J.17
Frachette, M.J.18
Tartaglia, J.19
McCormack, S.20
Babiker, A.21
Weber, J.22
Pantaleo, G.23
more..
-
48
-
-
77951489485
-
Phenotypic and functional profile of hiv-inhibitory cd8 t cells elicited by natural infection and heterologous prime/boost vaccination
-
Freel SA, Lamoreaux L, Chattopadhyay PK, Saunders K, Zarkowsky D, Overman RG, Ochsenbauer C, Edmonds TG, Kappes JC, Cunningham CK, Denny TN, Weinhold KJ, Ferrari G, Haynes BF, Koup RA, Graham BS, Roederer M, Tomaras GD. 2010. Phenotypic and functional profile of HIV-inhibitory CD8 T cells elicited by natural infection and heterologous prime/boost vaccination. J. Virol. 84:4998-5006.
-
(2010)
J. Virol
, Issue.84
, pp. 4998-5006
-
-
Freel, S.A.1
Lamoreaux, L.2
Chattopadhyay, P.K.3
Saunders, K.4
Zarkowsky, D.5
Overman, R.G.6
Ochsenbauer, C.7
Edmonds, T.G.8
Kappes, J.C.9
Cunningham, C.K.10
Denny, T.N.11
Weinhold, K.J.12
Ferrari, G.13
Haynes, B.F.14
Koup, R.A.15
Graham, B.S.16
Roederer, M.17
Tomaras, G.D.18
-
49
-
-
84863774072
-
Broadly neu-tralizing antibodies present new prospects to counter highly antigenically diverse viruses
-
Burton DR, Poignard P, Stanfield RL, Wilson IA. 2012. Broadly neu-tralizing antibodies present new prospects to counter highly antigenically diverse viruses. Science 337:183-186.
-
(2012)
Science
, vol.337
, pp. 183-186
-
-
Burton, D.R.1
Poignard, P.2
Stanfield, R.L.3
Wilson, I.A.4
-
50
-
-
84861986980
-
Hiv vaccine development: Challenges and opportunities towards solving the hiv vaccine-neutralizing antibody problem
-
Koff WC. 2012. HIV vaccine development: challenges and opportunities towards solving the HIV vaccine-neutralizing antibody problem. Vaccine 30:4310-4315.
-
(2012)
Vaccine
, vol.30
, pp. 4310-4315
-
-
Koff, W.C.1
-
51
-
-
82955241840
-
Rational design of vaccines to elicit broadly neutralizing antibodies to hiv-1
-
doi:10.1101/cshperspect.a007278
-
Kwong PD, Mascola JR, Nabel GJ. 2011. Rational design of vaccines to elicit broadly neutralizing antibodies to HIV-1. Cold Spring Harbor Perspect. Med. 1:a007278. doi:10.1101/cshperspect.a007278.
-
(2011)
Cold Spring Harbor Perspect. Med
, Issue.1
-
-
Kwong, P.D.1
Mascola, J.R.2
Nabel, G.J.3
-
53
-
-
84863932778
-
Magnitude and breadth of the neutralizing antibody response in the rv144 and vax003 hiv-1 vaccine efficacy trials
-
Montefiori DC, Karnasuta C, Huang Y, Ahmed H, Gilbert P, de Souza MS, McLinden R, Tovanabutra S, Laurence-Chenine A, Sanders-Buell E, Moody MA, Bonsignori M, Ochsenbauer C, Kappes J, Tang H, Greene K, Gao H, Labranche CC, Andrews C, Polonis VR, Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Self SG, Berman PW, Francis D, Sinangil F, Lee C, Tartaglia J, Robb ML, Haynes BF, Michael NL, Kim JH. 2012. Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials. J. Infect. Dis. 206:431-441.
-
(2012)
J. Infect. Dis
, vol.206
, pp. 431-441
-
-
Montefiori, D.C.1
Karnasuta, C.2
Huang, Y.3
Ahmed, H.4
Gilbert, P.5
De Souza, M.S.6
McLinden, R.7
Tovanabutra, S.8
Laurence-Chenine, A.9
Sanders-Buell, E.10
Moody, M.A.11
Bonsignori, M.12
Ochsenbauer, C.13
Kappes, J.14
Tang, H.15
Greene, K.16
Gao, H.17
Labranche, C.C.18
Andrews, C.19
Polonis, V.R.20
Rerks-Ngarm, S.21
Pitisuttithum, P.22
Nitayaphan, S.23
Kaewkungwal, J.24
Self, S.G.25
Berman, P.W.26
Francis, D.27
Sinangil, F.28
Lee, C.29
Tartaglia, J.30
Robb, M.L.31
Haynes, B.F.32
Michael, N.L.33
Kim, J.H.34
more..
-
54
-
-
84859393693
-
Immune-correlates analysis of an hiv-1 vaccine efficacy trial
-
Haynes BF, Gilbert PB, McElrath MJ, Zolla-Pazner S, Tomaras GD, Alam SM, Evans DT, Montefiori DC, Karnasuta C, Sutthent R, Liao HX, DeVico AL, Lewis GK, Williams C, Pinter A, Fong Y, Janes H, DeCamp A, Huang Y, Rao M, Billings E, Karasavvas N, Robb ML, Ngauy V, de Souza MS, Paris R, Ferrari G, Bailer RT, Soderberg KA, Andrews C, Berman PW, Frahm N, De Rosa SC, Alpert MD, Yates NL, Shen X, Koup RA, Pitisuttithum P, Kaewkungwal J, Nitayaphan S, Rerks-Ngarm S, Michael NL, Kim JH. 2012. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N. Engl. J. Med. 366:1275-1286.
-
(2012)
N. Engl. J. Med
, vol.366
, pp. 1275-1286
-
-
Haynes, B.F.1
Gilbert, P.B.2
McElrath, M.J.3
Zolla-Pazner, S.4
Tomaras, G.D.5
Alam, S.M.6
Evans, D.T.7
Montefiori, D.C.8
Karnasuta, C.9
Sutthent, R.10
Liao, H.X.11
DeVico, A.L.12
Lewis, G.K.13
Williams, C.14
Pinter, A.15
Fong, Y.16
Janes, H.17
DeCamp, A.18
Huang, Y.19
Rao, M.20
Billings, E.21
Karasavvas, N.22
Robb, M.L.23
Ngauy, V.24
De Souza, M.S.25
Paris, R.26
Ferrari, G.27
Bailer, R.T.28
Soderberg, K.A.29
Andrews, C.30
Berman, P.W.31
Frahm, N.32
De Rosa, S.C.33
Alpert, M.D.34
Yates, N.L.35
Shen, X.36
Koup, R.A.37
Pitisuttithum, P.38
Kaewkungwal, J.39
Nitayaphan, S.40
Rerks-Ngarm, S.41
Michael, N.L.42
Kim, J.H.43
more..
-
55
-
-
84856482137
-
Vaccine protection against acquisition of neutralization-resistant siv challenges in rhesus monkeys
-
Barouch DH, Liu J, Li H, Maxfield LF, Abbink P, Lynch DM, Iampietro MJ, SanMiguel A, Seaman MS, Ferrari G, Forthal DN, Ourmanov I, Hirsch VM, Carville A, Mansfield KG, Stablein D, Pau MG, Schuitemaker H, Sadoff JC, Billings EA, Rao M, Robb ML, Kim JH, Marovich MA, Goudsmit J, Michael NL. 2012. Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys. Nature 482:89-93.
-
(2012)
Nature
, vol.482
, pp. 89-93
-
-
Barouch, D.H.1
Liu, J.2
Li, H.3
Maxfield, L.F.4
Abbink, P.5
Lynch, D.M.6
Iampietro, M.J.7
SanMiguel, A.8
Seaman, M.S.9
Ferrari, G.10
Forthal, D.N.11
Ourmanov, I.12
Hirsch, V.M.13
Carville, A.14
Mansfield, K.G.15
Stablein, D.16
Pau, M.G.17
Schuitemaker, H.18
Sadoff, J.C.19
Billings, E.A.20
Rao, M.21
Robb, M.L.22
Kim, J.H.23
Marovich, M.A.24
Goudsmit, J.25
Michael, N.L.26
more..
-
56
-
-
77957752730
-
Vaccination with a modified vaccinia virus ankara (mva)-vectored hiv-1 immunogen induces modest vectorspecific t cell responses in human subjects
-
Howles S, Guimarães-Walker A, Yang H, Hancock G, di Gleria K, Tarragona-Fiol T, Hayes P, Gilmour J, Bridgeman A, Hanke T, McMichael A, Dorrell L. 2010. Vaccination with a modified vaccinia virus Ankara (MVA)-vectored HIV-1 immunogen induces modest vectorspecific T cell responses in human subjects. Vaccine 28:7306-7312.
-
(2010)
Vaccine
, vol.28
, pp. 7306-7312
-
-
Howles, S.1
Guimarães-Walker, A.2
Yang, H.3
Hancock, G.4
Di Gleria, K.5
Tarragona-Fiol, T.6
Hayes, P.7
Gilmour, J.8
Bridgeman, A.9
Hanke, T.10
McMichael, A.11
Dorrell, L.12
|